ArticleFrontiers in surgery2026
Application of tranexamic acid during debridement for proximal-to-mid humeral chronic osteomyelitis: evaluation of blood management and infection-control safety.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adequate exposure and thorough removal of infected tissue are essential during debridement for chronic osteomyelitis. In proximal-to-mid humeral chronic osteomyelitis, complex anatomy, abundant musculature, and limited tourniquet feasibility may cause diffuse bleeding, impaired visualization, and prolonged surgery. Although tranexamic acid (TXA) is widely used for orthopaedic blood management, its infection-control safety in infected bone debridement remains unclear. We evaluated preoperative intravenous TXA in this setting. Methods: This single-center retrospective cohort study included patients undergoing debridement for chronic osteomyelitis of the proximal or mid-humerus between January 2020 and March 2025. Patients were grouped by preoperative intravenous TXA use; the TXA group received 1.0 g approximately 30 min before surgery. Primary outcomes were second-stage frozen-section neutrophil count, unplanned repeat debridement, infection recurrence, and venous thromboembolic events. Secondary outcomes were operative time, estimated intraoperative blood loss, postoperative drainage volume, recorded perioperative blood loss, and transfusion. Results: Eighty-two patients were included: 47 received TXA and 35 did not. Baseline characteristics were generally comparable. Operative time (139.2 ± 13.4 vs. 148.7 ± 11.8 min, Conclusions: In selected patients without TXA contraindications, preoperative intravenous TXA was associated with lower perioperative blood-loss measures and shorter operative time, with no statistically detectable increase in infection-control adverse signals. No clinically diagnosed venous thromboembolic events were documented during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.